Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Fabry disease (FD) is a progressive multisystemic disorder, treatable with recombinant enzyme replacement therapy (agalsidase). However, recent studies suggest an endogenous inhibition of agalsidase in patients with FD, as reported for other lysosomal storage diseases. To assess the clinical consequences of serum-mediated agalsidase inhibition in affected patients, we determined the agalsidase inhibition status of 168 patients (68 male) with FD and compared outcomes of inhibition-positive patients with those of inhibition-negative patients. The assessment included clinical events during time on agalsidase, determination of renal and cardiac function, and evaluation of FD-related symptoms. The frequency of serum-mediated agalsidase inhibition was 40% in agalsidase-treated males. Inhibition did not depend on the compound initially used (agalsidase-α or -β). Agalsidase inhibition was associated with higher lyso-globotriaosylceramide levels and worse disease severity scores in patients. Compared with agalsidase inhibition-negative men, agalsidase inhibition-positive men showed greater left ventricular mass (P=0.02) and substantially lower renal function (difference in eGFR of about -30 ml/min per 1.73 m(2); P=0.04), which was confirmed by a longitudinal 5-year retrospective analysis. Additionally, affected patients presented more often with FD-typical symptoms, such as diarrhea, fatigue, and neuropathic pain, among others. Therefore, patients with poor clinical outcome on agalsidase should be tested for agalsidase inhibition. Future studies are warranted to determine if affected patients with FD benefit from acute reduction of anti-agalsidase antibodies or long-term immune modulation therapies to suppress agalsidase inhibition and to identify mechanisms that minimize antibody generation against agalsidase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603 · cited 1×
“Creatinine-based eGFR was calculated via CKD-EPI formula according to Levey et al. 2009.”
MethodLang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Zarate, Y. A., & Hopkin, R. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61589-5 · Cited by 795
ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography
Douglas, P. S., Garcia, M. J., Haines, D. E., Lai, W. W., Manning, W. J., Patel, A. R., Picard, M. H., Polk, D. M., Ragosta, M., Ward, R. P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.11.002 · Cited by 673
SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE
Ng, M., Uffon, N. A. G., Ilcox, W. I. R. W., Ermain, P. G., Ee, P., Aldek, S. T. W., Aplan, L. O. C., Inthorst, E. L., & Esnick, R. O. J. D. (2001) · Cited by 482
Desnick, R. J., Allen, K. Y., Desnick, S. J., Raman, M. K., Bernlohr, R. W., & Krivit, W. A. (1973) · PubMed · Cited by 304
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
Linthorst, G. E., Hollak, C. E. M., Donker-Koopman, W. E., Strijland, A., & Aerts, J. M. F. G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00924.x · Cited by 282
Whybra, C., Kampmann, C., Krummenauer, F., Ries, M., Mengel, E., Miebach, E., Baehner, F., Kim, K., Bajbouj, M., Schwarting, A., et al. (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00219.x · Cited by 266
Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease
Tøndel, C., Bostad, L., Larsen, K. K., Hirth, A., Vikse, B. E., Houge, G., & Svarstad, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030316 · Cited by 237
Mayes, J. S., Scheerer, J. B., Sifers, R. N., & Donaldson, M. L. (1981) · Clinica Chimica Acta · doi:10.1016/0009-8981(81)90384-3 · Cited by 218
Rombach, S. M., Aerts, J. M. F. G., Poorthuis, B. J. H. M., Groener, J. E. M., Donker‐Koopman, W. E., Hendriks, E., Mirzaian, M., Kuiper, S., Wijburg, F. A., Hollak, C. E. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047805 · Cited by 134
Rosenberg, M., Kingma, W., Fitzpatrick, M. A., & Richards, S. M. (1999) · Blood · doi:10.1182/blood.v93.6.2081.406k07_2081_2088 · Cited by 120
Bénichou, B., Goyal, S., Sung, C., Norfleet, A. M., & O’Brien, F. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.004 · Cited by 109
A validated disease severity scoring system for Fabry disease
Giannini, E. H., Mehta, A. B., Hilz, M. J., Beck, M., Bichet, D. G., Brady, R. O., West, M. L., Germain, D. P., Wanner, C., Waldek, S., et al. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.10.178 · Cited by 80
Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry
Wilcox, W. R., Linthorst, G. E., Germain, D. P., Feldt‐Rasmussen, U., Waldek, S., Richards, S. M., Beitner‐Johnson, D., Cizmarik, M., Cole, J. A., Kingma, W., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.12.006 · Cited by 78
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch
Weidemann, F., Krämer, J., Duning, T., Lenders, M., Canaan‐Kühl, S., Krebsová, A., González, H. G., Sommer, C., Üçeyler, N., Niemann, M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060585 · Cited by 73
Self-citationManagement of Neutralizing Antibody to Ceredase in a Patient With Type 3 Gaucher Disease
Brady, R. O., Murray, G. J., Oliver, K. L., Leitman, S. F., Sneller, M. C., Fleisher, T. A., Barton, N. W., & Collaborators (1997) · PEDIATRICS · doi:10.1542/peds.100.6.e11 · Cited by 53
Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase
Brands, M. M. M. G., Hoogeveen‐Westerveld, M., Kroos, M. A., Nobel, W., Ruijter, G. J. G., Özkan, L., Plug, I., Grinberg, D., Vilageliu, L., Halley, D. J. J., et al. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-51 · Cited by 46
Immune response to enzyme replacement therapy in Fabry disease: Impact on clinical outcome?
Hollak, C. E. M., & Linthorst, G. E. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.013 · Cited by 29
Warnock, D. G., & Mauer, M. S. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013121322 · Cited by 23
The immunogenicity of therapeutic proteins and the fabry antibody standardization initiative
Schellekens, H. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80041-0 · Cited by 19
Markić, J., Polić, B., Kuzmanić-Šamija, R., Marušić, E., Stričević, L., Metličić, V., & Meštrović, J. (2011) · JIMD Reports · doi:10.1007/8904_2011_34 · Cited by 14
Research works printed but not linked: 1
- Kidney Disease. Improving Global Outcomes (KDIGO) CKD Work Group : KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 3[Suppl]: 1–150, 2013 [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&title=KDIGO%202012%20Clinical%20Practice%20Guideline%20for%20the%20Evaluation%20and%20Management%20of%20Chronic%20Kidney%20Disease.&volume=3&issue=Suppl&publication_year=2013&pages=1-150&)]
Cited by
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Although ERT is the current standard of care for patients with Fabry, it does have its limitations producing increased interest in gene replacement therapies.(252,253) Of the five gene replacement studies to date, two of them use an ex vivo approach (AVROBIO and University Health Network, Toronto), whereas two others…”
BackgroundFabry disease revisited: Management and treatment recommendations for adult patients
Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.02.014 · Cited by 650
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510198 · Cited by 555
Hughes, D. A., Nicholls, K., Shankar, S. P., Sunder-Plassmann, G., Koeller, D., Nedd, K., Vockley, G., Hamazaki, T., Lachmann, R., Ohashi, T., et al. (2017) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-104178 · Cited by 386
Germain, D. P., Elliott, P. M., Falissard, B., Fomin, V. V., Hilz, M. J., Jovanovic, A., Kantola, I., Linhart, A., Mignani, R., Namdar, M., et al. (2019) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2019.100454 · Cited by 233
“Eight mixed-ERT OS publications (including some large, long-term studies including ≤100 patients followed for ≤120 months) agreed that ERT might slow the decrease in eGFR [51,103,104,107,109,112,114,116].”
BackgroundInfluential
Metadata
- Authors
- Lenders, M., Stypmann, J., Duning, T., Schmitz, B., Brand, S.-M., & Brand, E.
- Affiliations
- University Hospital Münster (DE)
- Corresponding author
- Lenders, Malte
- Brand, Eva
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-01
- Volume
- 27
- Issue
- 1
- Pages
- 256-264
- ISSN
- 1046-6673 (ISSN-L)
- PMC
- PMC4696578
- OpenAlex
- W2129050348
- Cited by
- 133
- References
- 27
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 14 · 2023: 15 · 2022: 13 · 2021: 10 · 2020: 18 · 2019: 7 · 2018: 18 · 2017: 9 · 2016: 9
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- Fabry disease, enzyme replacement therapy, anti-enzyme antibodies, left ventricular mass, renal function, disease severity, lysosomal storage disease, neuropathic pain, immunomodulation
- MeSH terms
- Adult, alpha-Galactosidase, Fabry Disease, Female, Humans, Male, Middle Aged, Retrospective Studies, Treatment Failure, Enzyme Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.